arexvy news - Search News

GSK, Arexvy

GSK’s Arexvy Vaccine Shows Promise for Broader Use

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which shows potential in

The Pharma Letter · 2d

New data for GSK’s Arexvy RSV vaccine

US pharma major GSK yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due to certain underlying medical conditions and in adults who are immunocompromised.

Business Insider · 2d

GSK reports preliminary data for AREXVY

GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by

Pharmabiz · 2d

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr

Seeking Alpha on MSN · 3d

GSK reports positive data for RSV shot in younger, at-risk adults

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were at increased risk of developing lower respiratory tract disease as a result of the virus due to an underlying medical condition or being immunocompromised.

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

Graham Parry Recommends Sell Rating for GlaxoSmithKline Due to Concerns Over Arexvy Vaccine Efficacy and Safety

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on October 9. Graham ...

Monthly Prescribing Reference3d

Arexvy Looks Promising for RSV Protection in Younger At-Risk and Immunocompromised Adults

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

FiercePharma3d

GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

McKnight's Long-Term Care News19d

RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

GSK, Arexvy

Related topics